Silexion Therapeutics Announces Exercise of Warrants
Expected cash proceeds come with new warrants and a lower exercise price for all outstanding Series E warrants.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Silexion Therapeutics (SLXN) signed agreements for the immediate exercise of Series E warrants covering up to 3,216,928 ordinary shares.
The exercise price was reduced to $0.2603 per share. Gross proceeds are expected to be $837,366.36 before placement agent fees and estimated offering expenses. The offering is expected to close on or about September 29, 2026. In exchange for the cash exercise, Silexion will issue Series F and Series G warrants, each covering up to 3,216,928 shares at $0.2603 per share. The new warrants become exercisable after an increase in authorized ordinary shares takes effect following shareholder approval. Silexion also reduced the exercise price to $0.2603 for all outstanding Series E warrants covering 3,846,161 shares, including those covered by the exercise agreements.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Hollow bars mark forward-looking points. How the balance works
Positive
- Major point. Forward-looking: it has not happened yet and may not happen.$837,366.36 in gross proceeds is expected from the Series E warrant exercise, before fees and expenses. 61% of market cap
Negative
- Major point. Forward-looking: it has not happened yet and may not happen.Exercise of Series E warrants covering up to 3,216,928 ordinary shares will dilute existing holders.
- Major point. Forward-looking: it has not happened yet and may not happen.Series F warrants covering up to 3,216,928 shares at $0.2603 per share add potential dilution.
- Major point. Forward-looking: it has not happened yet and may not happen.Series G warrants covering up to 3,216,928 shares at $0.2603 per share add potential dilution.
- Major pointAll outstanding Series E warrants covering 3,846,161 shares now have a reduced $0.2603 exercise price.
- Minor pointShareholder approval is needed before the authorized-share increase required to exercise the new warrants can take effect.
- Minor point. Forward-looking: it has not happened yet and may not happen.Placement agent fees and estimated offering expenses will reduce the expected gross proceeds.
News Explained
The new Series F and G warrants are unregistered, but Silexion has agreed to file an SEC registration statement covering resale of shares issued on exercise; registration alone does not sell those shares.
Details
Market move: SLXN +22.71% vs previous close. Series E warrant exercise
On Sep 29, the day this news came out, the latest delayed price for SLXN is 22.71% above the previous close. Our momentum scanner has recorded 57 alerts for this stock so far that day. The latest delayed price is $0.30. Relative volume is exceptionally heavy at 357.9x the average.
Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.
Key Figures
- Expected gross proceeds
- $837,366.36
- Before placement agent fees and estimated offering expenses
- Warrants exercised
- Up to 3,216,928 shares
- Outstanding Series E warrants covered by the immediate exercise agreements
- Reduced exercise price
- $0.2603 per share
- Applied to outstanding Series E warrants
- New warrant coverage
- 3,216,928 shares each
- Series F and Series G warrants
- Series F warrant term
- Five years
- From the later of the Authorized Share Increase Date and resale registration effectiveness
- Series G warrant term
- Twenty-four months
- From the later of the Authorized Share Increase Date and resale registration effectiveness
- Series E warrants repriced
- 3,846,161 shares
- All outstanding Series E warrants
Previous Offering Reports
-
Priced Series E warrants covering 3,846,161 shares at $0.65; gross proceeds expected near $2.5 million.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
rna interference (rnai) technical
form s-1 regulatory
private placement financial
small interfering rna (sirna) technical
AI-generated analysis. How Rhea-AI works. Not financial advice.
Cayman Islands, Sept. 29, 2026 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion” or the “Company”), a clinical-stage biotechnology company pioneering RNA interference (RNAi) therapies for KRAS-driven cancers, today announced the entry into definitive agreements for the immediate exercise of certain outstanding series E warrants to purchase up to an aggregate of 3,216,928 of the Company’s ordinary shares originally issued in August 2026 having a reduced exercise price of
H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering.
In consideration for the immediate exercise of the warrants for cash, the Company will issue new unregistered Series F warrants to purchase up to 3,216,928 of the Company’s ordinary shares and new unregistered Series G warrants to purchase up to 3,216,928 of the Company’s ordinary shares. The new warrants will have an exercise price of
The new warrants described above were offered in a private placement pursuant to an applicable exemption from the registration requirements of the Securities Act of 1933, as amended (the “1933 Act”) and, along with the ordinary shares issuable upon their exercise, have not been registered under the 1933 Act, and may not be offered or sold in the United States absent registration with the Securities and Exchange Commission (“SEC”) or an applicable exemption from such registration requirements. The Company has agreed to file a registration statement with the SEC covering the resale of the ordinary shares issuable upon exercise of the new warrants (the “Resale Registration Statement”).
In connection with the offering, the Company is reducing the exercise price for all outstanding series E warrants to purchase 3,846,161 ordinary shares, including the series E warrants to purchase up to 3,216,928 ordinary shares referred to above, such that all outstanding series E warrants have a reduced exercise price of
This press release shall not constitute an offer to sell or a solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction.
About Silexion Therapeutics
Silexion Therapeutics is a pioneering clinical-stage, oncology-focused biotechnology company dedicated to the development of innovative treatments for unsatisfactorily treated solid tumor cancers that have the mutated KRAS oncogene, generally considered to be the most common oncogenic gene driver in human cancers. The Company conducted a Phase 2a clinical trial in its first-generation product candidate, which showed a positive trend in comparison to the control of chemotherapy alone, and is now advancing its lead, second-generation, product candidate, SIL204, a small interfering RNA (siRNA), through Phase 2/3 clinical evaluation. Silexion is committed to pushing the boundaries of therapeutic advancements in the field of oncology and further developing its lead product candidate for locally advanced pancreatic cancer. For more information, please visit: https://silexion.com
Notice Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the federal securities laws. All statements other than statements of historical fact contained in this communication, including statements regarding the completion of the offering, the satisfaction of customary closing conditions related to the offering, the receipt of shareholder approval and the intended use of net proceeds from the offering, are forward-looking statements. These forward-looking statements are generally identified by terminology such as “may”, “should”, “could”, “might”, “plan”, “possible”, “expect”, “intend”, “will”, “estimate”, “anticipate”, “believe”, “predict”, or “potential”, or the negatives of these terms or variations of them or similar terminology. Forward-looking statements involve a number of risks, uncertainties, and assumptions, and actual results or events may differ materially from those projected or implied in those statements. Important factors that could cause such differences include, but are not limited to: (i) the inherent uncertainties associated with translational and preclinical research and drug development, including the risk that preliminary in vitro findings regarding cellular uptake, lipoprotein association, and gene silencing may not translate to in vivo pharmacokinetic models or clinical outcomes; (ii) Silexion’s ability to successfully complete additional preclinical and pharmacokinetic studies and initiate and conduct clinical trials, including the Phase 2/3 trial of SIL204 in locally advanced pancreatic cancer; (iii) Silexion’s strategy, future operations, financial position, projected costs, prospects, and plans; (iv) the impact of the regulatory environment and compliance complexities, including site-level approvals, conditions, and clearances required prior to study commencement at clinical sites in Israel, Germany, and other jurisdictions; (v) expectations regarding future partnerships or other relationships with third parties; (vi) Silexion’s future capital requirements and sources and uses of cash, including its ability to obtain additional capital; (vii) Silexion’s ability to maintain its Nasdaq listing; and (viii) other risks and uncertainties set forth in the documents filed by the Company with the SEC, including the Company’s Annual Report on Form 10-K for the year ended December 31, 2025, filed with the SEC on March 17, 2026, and the Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2026, filed with the SEC on August 14, 2026. Silexion cautions you against placing undue reliance on forward-looking statements, which reflect current beliefs and are based on information currently available as of the date a forward-looking statement is made. Forward-looking statements set forth herein speak only as of the date they are made. Silexion undertakes no obligation to revise forward-looking statements to reflect future events, changes in circumstances, or changes in beliefs, except as otherwise required by law.
Company Contact
Silexion Therapeutics Corp
Ms. Mirit Horenshtein Hadar, CFO
info@silexion.com
Investor Relations Contact
Arx Investor Relation
North American Equities Desk
silexion@arxhq.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
How much does Silexion Therapeutics expect from the Series E warrant exercise?
Silexion expects $837,366.36 in gross proceeds from the exercise, before deducting placement agent fees and estimated offering expenses. The exercise agreements cover warrants to purchase up to 3,216,928 ordinary shares at a reduced price of $0.2603 per share.
When do Silexion Therapeutics’ new Series F and Series G warrants expire?
The Series F warrants expire five years after the later of the authorized-share increase taking effect and the resale registration statement taking effect. The Series G warrants expire twenty-four months after the later of those same events.